SAN DIEGO, June 24, 2011 /PRNewswire/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective analysis of more than 778,000 ...

SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that ...

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...

Study over 24 weeks on patients with type 2 diabetes Says exenatide once-weekly shows superior glucose control Dec 15 (Reuters) - Amylin Pharmaceuticals Inc reported positive data from a study that ...

BOSTON (Reuters) - Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently linked with six deaths from pancreatitis, reduced ...

The FDA has approved Byetta (exenatide injection, from Amylin and Lilly), a GLP-1 receptor agonist, for use as monotherapy along with diet and exercise to improve glycemic control in adults with type ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes. Byetta can cause side effects that range from mild to serious. Examples include nausea and vomiting. The active ...

Ever wonder why acquisition-minded CEO John Lechleiter has been cool to the idea of Eli Lilly and Co. buying Amylin Pharmaceuticals Inc., Lilly’s partner on the diabetes medicine Byetta? One reason ...

Eli Lilly and Co. will have to wait a little longer before selling a once-weekly version of its diabetes drug Byetta. The U.S. Food and Drug Administration told Lilly and its development partners on ...

Byetta (exenatide) is a prescription drug that’s used to treat type 2 diabetes in adults. This drug can interact with other medications and some supplements. For example, Byetta can interact with ...